Your Patient Can't Find Cyltezo — Here's How You Can Help

You prescribed Cyltezo (Adalimumab-adbm) because it's a proven, FDA-interchangeable biosimilar to Humira with strong clinical data. But your patient is calling back frustrated: their pharmacy doesn't carry it, or their insurance is pushing them toward a different product. This scenario is playing out in rheumatology, gastroenterology, and dermatology practices across the country.

As a prescriber, you're in a unique position to help patients navigate these barriers. Here's a practical guide to getting your patients their Cyltezo — or an appropriate alternative — without treatment interruptions.

Current Availability: What's Actually Happening

Cyltezo is not in shortage from a manufacturing standpoint. Boehringer Ingelheim continues to produce and distribute the medication. The challenges are at the pharmacy and formulary level:

• PBM formulary shifts: Several major PBMs, including Optum Rx, moved away from Cyltezo as a preferred product in 2025, reducing pharmacy demand.
• Market crowding: With 10+ adalimumab biosimilars available, pharmacies stock only what their top PBM contracts demand.
• Specialty vs. retail divide: Biologics increasingly flow through specialty pharmacy channels, leaving retail pharmacies with limited or no stock.

For a detailed analysis, see our provider briefing on Cyltezo access in 2026.

Why Patients Can't Find It

When a patient tells you they can't find Cyltezo, the root cause is usually one of these:

1. Their retail pharmacy doesn't stock it. Chain pharmacies carry whichever adalimumab product aligns with their most common PBM contracts.
2. Their insurance doesn't prefer it. If Cyltezo isn't on the formulary, the pharmacy has no incentive to stock it, and the patient faces higher costs.
3. They're not using a specialty pharmacy. Many patients default to their usual retail pharmacy, which may not handle biologics efficiently.
4. Prior authorization is pending or denied. PA delays can cascade into pharmacy access issues.

What Providers Can Do: 5 Steps

Step 1: Check the Patient's Formulary Before Prescribing

Before writing a Cyltezo prescription, verify which adalimumab product is preferred by the patient's insurance plan. This single step prevents the most common access problem. Your practice's prior authorization team or specialty pharmacy liaison can often look this up quickly.

If Cyltezo is non-preferred but clinically appropriate, be prepared to submit a prior authorization or formulary exception request. Document why Cyltezo is preferred for this patient (e.g., interchangeable status, citrate-free formulation, prior response).

Step 2: Route Prescriptions Through Specialty Pharmacies

Specialty pharmacies are significantly more likely to have Cyltezo in stock compared to retail pharmacies. Benefits of specialty pharmacy routing include:

• Higher likelihood of having the prescribed product available
• Home delivery with temperature-controlled shipping
• Integrated prior authorization and copay assistance support
• Adherence monitoring and patient follow-up

Many health systems have preferred specialty pharmacy partnerships. If your practice doesn't have one, consider establishing a referral relationship with one or two specialty pharmacies that reliably stock adalimumab products.

Step 3: Use Real-Time Availability Tools

Medfinder for Providers allows you to check real-time pharmacy stock for Cyltezo and direct patients to specific pharmacies with confirmed availability. This eliminates the frustrating cycle of patients calling multiple pharmacies only to come up empty.

Integrate Medfinder checks into your workflow: when a patient reports access issues, your medical assistant or care coordinator can quickly identify a pharmacy with stock.

Step 4: Provide Bridge Samples When Needed

If a patient is at risk of missing a dose while navigating access barriers, consider providing bridge samples. Boehringer Ingelheim's professional portal (pro.boehringer-ingelheim.com) offers information on sample availability. Bridge samples from Humira (the reference product) can also work, since Cyltezo is interchangeable.

Document the bridge supply and ensure the patient's ongoing prescription is being processed in parallel.

Step 5: Proactively Communicate With Patients

Patients on biologics benefit from proactive communication about potential access challenges. At the time of prescribing, let patients know:

• Their medication may need to be filled through a specialty pharmacy
• Prior authorization may take 5–10 business days
• They should start the refill process at least one week before their next dose
• They can use Medfinder to check stock independently

Setting expectations upfront reduces patient anxiety and prevents emergency access situations.

When to Consider Alternatives

If Cyltezo remains inaccessible despite your efforts, switching to another adalimumab biosimilar is clinically straightforward. The leading alternatives include:

• Amjevita (Adalimumab-atto): Interchangeable, citrate-free, widely covered by PBMs in 2025–2026.
• Hyrimoz (Adalimumab-adaz): Interchangeable, citrate-free, competitive pricing.
• Hadlima (Adalimumab-bwwd): Biosimilar with high-concentration citrate-free option available.

For a detailed comparison, see Alternatives to Cyltezo.

Clinical studies demonstrate that switching between adalimumab products does not result in loss of efficacy or increased immunogenicity. No wash-out period is required.

Workflow Tips for Your Practice

• Create a formulary cheat sheet. Maintain a quick-reference document of preferred adalimumab products by major PBM. Update it quarterly as formularies change.
• Designate a biologic access coordinator. Assign a staff member to manage prior authorizations, specialty pharmacy coordination, and patient access issues for biologic medications.
• Build specialty pharmacy relationships. Work with 2–3 specialty pharmacies that reliably stock multiple adalimumab products. This gives you options when one product is unavailable.
• Track access outcomes. Monitor how often patients report access issues and which products are most frequently unavailable. Use this data to inform your prescribing patterns.
• Leverage manufacturer resources. Boehringer Ingelheim's Cyltezo hub services can assist with prior authorization support, copay programs, and pharmacy location. Visit pro.boehringer-ingelheim.com/us/products/cyltezo/copay-and-support.

Final Thoughts

Helping patients access Cyltezo requires more than writing a prescription. In today's fragmented adalimumab market, providers who proactively verify formulary status, route through specialty channels, and equip patients with tools like Medfinder will see fewer treatment interruptions and better outcomes.

The goal is simple: keep patients on therapy. Whether that's with Cyltezo or an equally effective alternative, your guidance makes the difference between a filled prescription and a frustrated patient.